Newsletter Sign Up

StopAfib.org

Newsletter Signup
Get in Rhythm. Stay in Rhythm.™ Atrial Fibrillation Patient Conference. Sept 15-17, 2016, in Dallas, TX
Get in Rhythm. Stay in Rhythm.™ Atrial Fibrillation Patient Conference. Sept 15-17, 2016, in Dallas, TX

Atrial Fibrillation Medication Study Now Enrolling

Study will determine how well medication reduces the amount of time your heart is in afib

September 16, 2015

A research study is currently enrolling patients who have paroxysmal atrial fibrillation (afib that comes and goes). This clinical research study, sponsored by Bristol-Myers Squibb, will evaluate the effectiveness and how well the body tolerates an experimental drug (BMS-919373).

The study will compare the safety and effectiveness of this experimental medication to a placebo (an inactive substance) in determining how well it reduces the amount of time your heart is in atrial fibrillation. Those who are eligible to enroll in this 87 day study will be randomly divided into 4 different groups. Three groups will receive the study medication at different doses, and the fourth group will receive a placebo. Study procedures will be conducted on an outpatient basis at sites in the United States and Canada.

To be eligible, your heart will need to be in afib a certain amount of time. The study doctor will run a noninvasive test, at no cost to you, to determine if you are eligible to participate. If you qualify, you will discontinue your current antiarrhythmic medication in order to evaluate the safety and effectiveness of this experimental medication, or the placebo, throughout your participation in the study.

For more information or to find a study site, visit afibtrial.com or clinicaltrials.gov.

Back to News

Last Modified September 16, 2015

Get Started Learning About Atrial Fibrillation

Afib Community

Blog Forum

Locate Help

Afib services near you

USA Locations International Locations List Your Afib Services

We comply with the HONcode standard for trustworthy health information: verify here.

Newsletter Sign Up